Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MDGL 
Madrigal Pharmaceuticals Inc (MDGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MDGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.21% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.31B USD | Price to earnings Ratio - | 1Y Target Price 414.07 |
Price to earnings Ratio - | 1Y Target Price 414.07 | ||
Volume (30-day avg) 384792 | Beta -0.41 | 52 Weeks Range 189.00 - 377.46 | Updated Date 04/1/2025 |
52 Weeks Range 189.00 - 377.46 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -21.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -258.64% | Operating Margin (TTM) -64.84% |
Management Effectiveness
Return on Assets (TTM) -36.98% | Return on Equity (TTM) -80.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6512699746 | Price to Sales(TTM) 40.6 |
Enterprise Value 6512699746 | Price to Sales(TTM) 40.6 | ||
Enterprise Value to Revenue 36.16 | Enterprise Value to EBITDA -8.32 | Shares Outstanding 22080200 | Shares Floating 11365807 |
Shares Outstanding 22080200 | Shares Floating 11365807 | ||
Percent Insiders 8.74 | Percent Institutions 105.1 |
Analyst Ratings
Rating 4.31 | Target Price 373 | Buy 4 | Strong Buy 9 |
Buy 4 | Strong Buy 9 | ||
Hold 2 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Madrigal Pharmaceuticals Inc
Company Overview
History and Background
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with unmet medical needs. It was founded in 2006 and has since focused on developing a selective thyroid hormone receptor-beta (THR-u03b2) agonist called resmetirom.
Core Business Areas
- NASH Drug Development: Madrigal's primary focus is the development and commercialization of resmetirom for the treatment of NASH. This includes clinical trials, regulatory submissions, and eventual commercialization activities.
- Research and Development: Ongoing research and development efforts to explore additional therapeutic applications for THR-u03b2 agonists and related compounds.
Leadership and Structure
Bill Sibold serves as the CEO. The company has a typical corporate structure with a board of directors and executive leadership team overseeing various functional areas, including research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Resmetirom: Resmetirom is an oral, once-daily thyroid hormone receptor (THR)-u03b2 selective agonist. It is Madrigal's lead product candidate for the treatment of NASH. The FDA has approved Resmetirom. The competitors include Viking Therapeutics (VKTX) and Akero Therapeutics (AKRO). Market share data and revenue from this product are not yet available.
Market Dynamics
Industry Overview
The NASH market is large and growing, driven by the increasing prevalence of obesity and diabetes. There is significant unmet need for effective treatments, making it an attractive area for pharmaceutical development.
Positioning
Madrigal is positioned as a leader in the NASH space, with resmetirom being one of the most advanced drug candidates in development. Its competitive advantage lies in its THR-u03b2 selective mechanism of action, which aims to improve liver health without significant side effects.
Total Addressable Market (TAM)
The estimated TAM for NASH is billions of dollars annually, with projections varying based on diagnosis rates and treatment costs. Madrigal is positioned to capture a significant portion of this market with successful commercialization of resmetirom.
Upturn SWOT Analysis
Strengths
- Advanced stage drug candidate (resmetirom)
- Selective THR-u03b2 agonist mechanism
- Strong clinical trial results
- Breakthrough Therapy designation from FDA
- FDA Approval
Weaknesses
- Reliance on a single product candidate
- High development costs
- Uncertainty regarding commercial success
- Competition from other companies developing NASH treatments
Opportunities
- Expansion of resmetirom to other indications
- Partnerships with other pharmaceutical companies
- Increasing prevalence of NASH
- Potential for combination therapies
Threats
- Regulatory setbacks
- Clinical trial failures
- Competition from other NASH drugs
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- Viking Therapeutics (VKTX)
- Akero Therapeutics (AKRO)
- Intercept Pharmaceuticals (ICPT)
Competitive Landscape
Madrigal's advantage lies in its THR-u03b2 selective mechanism, but it faces competition from other companies with different approaches to treating NASH. The competitive landscape is rapidly evolving.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by investment in research and development. Future growth depends on the successful commercialization of resmetirom.
Future Projections: Analyst projections vary, but generally anticipate significant revenue growth following the potential approval of resmetirom.
Recent Initiatives: Recent initiatives include preparing for the commercial launch of resmetirom, expanding clinical trials to other NASH patient populations, and exploring potential partnerships.
Summary
Madrigal Pharmaceuticals is a clinical-stage company with a promising drug candidate, resmetirom, for NASH. The company's success hinges on the successful commercialization of resmetirom, facing challenges from competition and regulatory hurdles. Madrigal is well positioned to address the unmet medical need in the NASH market if it can successfully execute its commercial strategy. However, the company needs to carefully manage its financial resources and address potential setbacks during commercialization.
Similar Companies
- VKTX
- AKRO
- ICPT
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share is based on potential projected market share, not current data. Some financial data is omitted due to the nature of the company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Madrigal Pharmaceuticals Inc
Exchange NASDAQ | Headquaters West Conshohocken, PA, United States | ||
IPO Launch date 2007-02-06 | CEO, President & Director Mr. William J. Sibold | ||
Sector Healthcare | Industry Biotechnology | Full time employees 528 | Website https://www.madrigalpharma.com |
Full time employees 528 | Website https://www.madrigalpharma.com | ||
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.